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Clinical trials of adoptive transfer of autologous tumor inﬁltrating lymphocytes (TILs) to patients with advanced malignant
melanoma have shown remarkable results with objective clinical responses in 50% of the treated patients. In order to initiate
a clinical trial in melanoma, we have established a method for expanding TILs to clinical relevant quantities in two steps with
in 8 weeks. Further characterization of expanded TILs revealed an oligoclonal composition of T-cells with an eﬀector memory
like phenotype. When autologous tumor was available, TILs showed speciﬁc activity in all patients tested. TIL cultures contained
speciﬁcity towards tumor cells as well as peptides derived from tumor-associated antigens (TAAs) during expansion procedures.
1.Introduction
The incidence of malignant melanoma is increasing world-
wide, and upon dissemination has a very poor prognosis
[1]. Only two systemic treatments are approved for dissem-
inated disease and encompass IL-2 based immunotherapy
(16% response rate and 6% complete responses) [2]a n d
dacarbazine (6%–15% response rate with no improved sur-
vival) [3]. However, results from clinical trials of TIL-
based immunotherapy conducted at two centres has shown
50% response rates in patients with advanced disease, and
responses were long lasting [4, 5]. TILs were reported to
be dominated by CD8+ T-cells and mediate speciﬁc killing
of autologous tumor in most patients [6]. Information on
TAA-derived peptide speciﬁcities in TIL has mainly shown
theoccasional largefrequencyof MART-1and gp100speciﬁc
T-cell populations. On the other hand, results on the clon-
otypic and phenotypic composition has been scarce; one
publication has revealed a mixed clonal content of TIL by
FACS analysis [7], and two recent studies report surface
markers identical to memory like eﬀector T-cells from a lim-
ited patient material [8, 9].
In our study, we have analysed TIL characteristics from
17 melanoma patients, whereof ﬁve have undergone lym-
phodepletion and TIL-based ACT with low-dose IL-2.
2.Materialsand Methods
2.1. Patients. Patients referred to surgery for primary or
recurrent stage III-IV malignant melanoma were eligible for
the study. The study protocol was approved by the local
ethicscommittee,and all patientswere includedaftersigning
informed consent. Tumor material from the patients was
obtained from the surgically removed tumour within 30
minutes after surgery.
2.2. TIL Bulk Cultures and Rapid Expansion. The TIL cultur-
ing method was adapted from Dudley et al. [10] constituting
a two-step expansion process: (I) initiating bulk cultures
and (II) rapid expansion of selected bulk cultures with a
proliferative potential. Following surgical removal of tumor
tissue from patients with MM the tumour sample were cut
into 1-2mm fragments. Fragmentswere subsequentlyplaced2 Journal of Skin Cancer
individually in 24-well culture plates (Nunc, Denmark) and
maintained in 2mL of culture medium (CM) containing
RPMI1640 (Invitrogen), penicillin, streptomycin, fungizone
(Bristol-Myers Squibb), 10% human serum (Sigma) and
7300 or 6000IU/mLIL-2 (Aldesleukin, Novartis). Each frag-
ment initiated an individual TIL culture which was main-
tained separately during subsequent expansion and activa-
tion.
Bulkcultureswere selected for further expansion accord-
ing to a rapid expansion protocol (REP). TIL were cocul-
tured with irradiated (40Gy) allogeneic PBMCs serving as
feeder cells in a ratio of 1:200 in a 1:1 mixture of CM
and AIM-V (Invitrogen) initially with 10%HS, and con-
taining 30ng/mLOKT-3 (Cilag AG, Suisse) and 7300 or
6000IU/mLIL-2 (Aldesleukin, Novartis) in upright T-ﬂasks.
REPs for preclinical purposes generally were initiated from
1 × 105 TIL per ﬂask, while 1 × 106 TIL were used per ﬂask
in clinical scale REPs. On day 5, half of the medium
was replaced with fresh medium containing AIM-V, CM
with 10% HS and 7300IU/mLIL-2. From there on, the
TIL concentration were maintained at 1 × 106 cells/mL by
adding AIM-V supplemented with Fungizone and 7300
or 6000IU/mLIL-2. Half of the patients TIL where cul-
tured in 7300IU/mlIL-2, while the other half received
6000IU/mLIL-2 during culturing.
2.3. Viability. Cell counting and viability testing were per-
formed by microscopy. Cells were stained with trypan blue
followed by counting of live and dead cells in a haemocy-
tometer.
2.4.Sterility Tests. BulkandREPcultureswere intermittently
sampled for microbiological testing of fungal and bacterial
contamination.
2.5. Peptides. We used the following HLA-A2 restricted
peptides: SUR1M2 (LMLGEFLKL), HTERT P540 (ILAK-
FLHWL), Cyclin B1 204 (ILIDWLVQV), MART-1 27–35
(AAGIGILTV ), and NY-ESO 1 157–165 (SLLMWITQC).
2.6. Cell Lines. Autologous tumor cell lines were established
from tumor fragments by outgrowth in 24 well or 6 well
plates (Nunc) in medium consisting of RPMI1640 (Invit-
rogen), penicillin, streptomycin, fungizone, 10% fetal calf
serum (Invitrogen), and SoluCortef (Pﬁzer).
Tumor cells were cryopreserved in 90% FCS and 10%
DMSO (Hospital Pharmacy, RegionH, Copenhagen, Den-
mark) and stored at −140◦C.
2.7. Flow Cytometry. Phenotyping were conducted using a
FACS-Aria with Diva software (from BD) and ﬂuorescence
conjugated monoclonal antibodies (mAb) against CD3
APC-Cy7, CD4 APC, CD8 PerCP, CD25 PE, CD27 PE,
CD45RA FITC, CD45RO PE, CD56 PE (all from BD),
CCR7 FITC (R&D systems), CD16 FITC (Dako), CD28
FITC (Immunotech), CD62Ligand PE (BD Pharmingen),
andCD57FITC(BDPharmingen)alongwith corresponding
isotypes.
2.8. T-Cell Receptor (TCR) Clonotype Mapping by Denaturing
Gradient Gel Electrophoresis (DGGE). RNA was extracted
using the NucleoSpin RNA II (Macherey-Nagel, Germany).
cDNA synthesis and quantitation of cDNA in each sample
was carried out as previously described [11].
For TCR clonotype mapping, cDNA was ampliﬁed using
a primer panel covering the 24 BV region families of
the TCR. Resulting PCR products are suited for DGGE
[12, 13]. Ampliﬁcations were carried out in a total volume
of 45μL containing 1xPCR buﬀer(50mMK Cl,20mMT ris
pH 8.4, 2.0mM MgCl2, 0.2mM cresol red, 12% sucrose,
0.005% (wt/v) BSA (Boehringer-Mannheim, Mannheim,
Germany)), 2.5pmol of each primer, 40mM dNTPs (Phar-
macia LKB, Uppsala, Sweden) and 1.25 units of AmpliTaq
polymerase (Perkin Elmer Cetus Corporation, Emeryville,
Calif, USA). Parameters and conditions used for ampliﬁca-
tion were 94◦Cf o r3 0 s e c . ,6 0 ◦C for 60sec., and 72◦Cf o r
60sec., as described, in [11, 12].
For DGGE 10μL aliquots were loaded onto a denaturing
gradient gel containing 6% polyacrylamide and a gradient
of urea and formamide ranging from 20% to 80%. Gels were
runat160Vfor4.5hin1xTAEbuﬀerkeptataconstanttem-
perature of 56◦C. After electrophoresis, the gel was stained
with SYBR Green I (Molecular Probes, Oregon, USA) and
visualized using the FLA-3000 ﬂuorescence detection system
(FUJI ﬁlm, Science Imaging Scandinavia, Sweden).
2.9. Elispot INFγ Measurement. Antitumor activity was
assessed with Elispot INFγ quantiﬁcation as described
previously [14]. In brief, nitrocellulose bottomed 96 well
plates (Multiscreen MAIP N45; Millipore, Denmark) were
coated with INFγ capturing antibody (1-DIK; Mabtech,
Sweden)andfurther washed and blockedwith RPMI1640.A
maximum of 1×105 eﬀector cells per well were either added
alone when stimulated by peptides, or in coculture with
target cells (1 × 104 cells per well) consisting of autologous
tumor cells. After a four-hour or overnight incubation pe-
riod, the medium was discarded and wells washed followed
by application of secondary biotinylated antibody (7-B6-1-
Biotin; Mabtech). The plates were incubated for one hour,
further washed, and avidin-enzyme (Streptavidin; Mabtech)
conjugate, were added to each well followed by one-hour in-
cubation at room temperature. Succeedingly, the wells were
washed and the enzyme substrate NBT/BCIP (nitro blue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate; Mab-
tech) were added into each well. The plates incubated at
room temperature for 2 to 10 minutes, while emerging pur-
ple spots developed. The reaction was terminated with tap
water. Spots were counted with the ImmunoSpot Series 2.0
Analyzer (CTL Analyzers) and the frequency of tumor
s p e c i ﬁ cT I Lc o u l db ec a l c u l a t e df r o mt h en u m b e r so fs p o t
forming cells. The assays were preferably done in triplets or
in duplicates in case of low cell numbers.
2.10. Cr Release Assay. As t a n d a r dC r 51-release assay was
used to quantify the speciﬁc cytotoxic ability of selected TIL
cultures.Inbrief, 5×103 Cr51-labeled tumorcells(duplicates
or triplicates) were cocultured with TIL (maximum E:TJournal of Skin Cancer 3
ratio of 100:1 and titrated) in RPMI containing 10% FCS
for a 4 hour incubation period. Thereafter, Cr51-release was
measuredandpercentageoftumorlysiscalculatedas(#count
− Min count)/(Max count −Min count) × 100%.
2.11. Statistical Analysis. We utilized Graphpad Prism sta-
tistical software to analyse for statistical diﬀerences, using




with either locally advanced or advanced disease from me-
tastasis localized either in lymph nodes (majority of spec-
imens) or subcutaneously. A minimum requirement of
1cm 3 of tumor was needed to ensure suﬃcient material for
TIL expansion. The mean age was 62 years with an equal
gender distribution. 12 of the patients had only been
treated surgically prior to inclusion, while ﬁve patients who
were included in our recent established clinical pilot trial
had previously received IL-2 and/or DC vaccination based
immunotherapies. Patients showed the following distribu-
tion of HLA-A types: one HLA-A1+, two HLA-A1/A3+, one
HLA-A3+, two HLA-A3/A11+, one HLA-A11+, one HLA-
A3+/A2+, four HLA-A2+, one HLA-A2/24+, and four non-
HLA-A1/A2/A3/A11/A24.
3.2.TILExpansion Kinetics. Lymphocytesmigratedoutfrom
the fragments within two-to-ﬁve days and expanded into a
conﬂuent layer before splitting the wells. Each well initiated
an individual bulk culture and were kept separated from
other cultures. TIL bulk cultures expanded to at least 5 ×
107 cells were considered suﬃciently expanding. This was
obtained in15out of17patients(88%)in 6%to 100% ofthe
bulk cultures (mean 58%) within 3–5 weeks. We found that
growthratesvaried markedly evenbetweenculturesfromthe
same patient, and there was no diﬀerence in success rate of
TIL growth from LN or SC tumor material, nor between the
IL-2 concentrations (data not shown).
We next tested the proliferative potential of a range of
bulk cultures from 12 of the 15 patients with suﬃciently
growing TIL. This rapid expansion procedure (REP)involves
the addition of allogeneic feeder cells and a CD3 antibody
and has shown to increase TIL expansion rates considerably,
in previously reports in both melanoma and head and
neck squamous cell carcinoma. Again, the kinetics could
vary between cultures from the same patient; however, the
procedure could eﬃciently expand TIL bulk cultures to over
a 1000-fold in more than half of the cultures in 2 weeks
(Figure 1).
3.3. Phenotypesand Clonal Composition. TIL were visualized
in the microscope, showing a blasted morphology related to
actively dividing lymphocytes laying either as single cells or
in clusters/clones.
In acquisition of cells by ﬂow cytometry, gating of viable
cells was performed on the basis of the forward and side
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Figure 1: REP fold-expansion. During two weeks 41 TIL cultures
(represented by single diamonds) reached a mean 1400 expansion
fold.
while NK cells (CD16/56+)( Figure 2) were consistently
absent. In bulk cultures, we observed a heterogeneous CD4+
and CD8+ T-cell distribution among cultures inter- and
intraindividually. There was, however, an overall skewing
towards a CD8+ (mean = 74% ± 24%, range 30%–94%)
T-cell predominance in relation to CD4+ T-cells (mean =
19.5% ± 23.5%, range 1%–64%). Next, we investigated the
occurrence of surface markers identifying T-cell memory
subsets, or alternatively, a diﬀerentiation path of eﬀector
cells, in the overall CD3+ population, and among CD4+ and
CD8+ T-cell subsets in comparison to TIL after two weeks of
REP (Figure 2). Overall, there was a distinct predominance
of CD45RO+ and CCR-7Lo/− T-cell populations before and
after REP identifying the cells as T eﬀector memory like.
TIL were further characterized by surface markers
according to a proposed model of eﬀector CD8+ T-cell
diﬀerentiation stages by Gattinoni et al. [15]. Expression of
the lymphoid homing marker CD62L was signiﬁcantly
reduced after REP in the CD3+ population and the CD8+
subsets and remained unchanged among the CD4+ sub-
sets. Concerning expression of costimulatory markers, we
observed a signiﬁcantly higher expression of CD27 among
CD8+ bulk TIL compared to CD4+ cells, while CD4+ cells
had sustained higher CD28 expression in bulk cultures and
after REP. Although there was a relatively high percentage
of CD27/28 double positive cells in a few bulk TIL, they
were downregulated after REP. Finally, there was a signiﬁcant
increase in the high-aﬃnity IL-2 receptor (CD25) after REP
intheCD4+ population.Inconclusion,theCD8+ population
express surface markers (CD45RO+, CCR-7Lo, CD62LLo,
CD27Lo,C D 2 8 Lo,a n dC D 5 7 Lo) resembling intermediate to
late-stage eﬀector cells as reported by other groups [8, 9, 16].
Selected expanded cultures were analyzed for the pres-
ence of clonally expanded T cells by RT-PCR/DGGE-based
TCRclonotypemapping. Analysis revealedthe presenceofat
least 10 diﬀerent T-cell clonotypes in bulk cultures as well as
in rapidly expanded cultures (data not shown). The results
support our previous ﬁndings in expanded TIL from head
and neck cancer patients, that expansion by high-dose IL-2
andCD3antibodyseemstosupportthecontinuedexpansion
of bulk T-cell clones.4 Journal of Skin Cancer
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Figure 2: Phenotypes. FACS determination of phenotypes of TIL cultures pre- (open circles) and post-REP (closed circles) are represented
from six patients. The overall T-cell eﬀector memory like phenotype (CD3+CD45R0+CCR-7Lo) is preserved after REP with a sustained low
expression of CD57 and intermediate CD25 expression. CD28 remains unchanged, while CD62L and CD27 is downregulated, indicating a
diﬀerentiation towards a later eﬀector stage.
3.4. Sustained Functional Capacity during Expansion. TIL
cultures from eight patients were selected to scrutinize the
presence of speciﬁc T-cell populations in bulk cultures and
after REP. Peptidesderivedfrom overexpressed (Telomerase,
Survivin, and CyclinB1),diﬀerentiation(MART-1)and can-
cer testis antigens (NY-ESO-1) served as known targets,
while autologous tumor cell lines presented a panel of un-
known antigen speciﬁcities. Elispot detectionof INFγ release
uponantigenicstimulationrevealedasustainedfunctionality
of TIL after REP. Due to the high sensitivity of the assay, weJournal of Skin Cancer 5


























































































Figure 3: Functional capacity. Determination of TAA peptide-speciﬁc populations in TIL pre- and post-REP. Results from Elispot detection
of INFγ in three patients exempliﬁes the general tendency of speciﬁcity retention, decline, and/or increase as a consequence of unspeciﬁc
stimulation during expansion procedures, (a) Autologous tumor cell lines were available from four patients, and all showed TIL with
antitumor activity by measuring INFγ in Elispot. Representative results of TIL from three patients show retained tumor-speciﬁc activity.
However, in patient MM + 16 we found a component of unspeciﬁc NK/LAK cell activity, which seemed to decline after REP, (b). Example
of preserved lytic capacity of TIL from MM 11 after REP. Both cultures show speciﬁc killing of two established autologous tumor cell lines.
Interestingly, Tumor 1 seems more immunogenic than Tumor 2, (c).
could follow the presence and loss of low-frequency single-
peptide-speciﬁcT-cell populations(Figure 3(a),occurring as
a consequence of an increase or decrease in cell number of
a given speciﬁc cell population, during the unspeciﬁc ex-
pansion procedures provided by IL-2 and anti-CD3. Autol-
ogous tumor cell lines were available in four patients, and
all patients contained TIL showing antitumor activity in
Elispot (Figure 3(b) and data not shown). The presence of
autologous tumor-speciﬁc T-cell populations was more
resistant during REP and showed a sustained functional
capacity.AlthoughT-cell-speciﬁcantitumoractivitywaspre-
dominatinginTIL,weobservedLAK/NKcellactivityinafew
cultures (Figure 3(b)) by unspeciﬁc engaging the cell lines
K562 and Daudi. Finally, we conﬁrmed a sustained tumo-
ricidal capacity of TIL after REP (Figure 3(c)) indicating that
TIL expanded to clinical relevant numbers (2400- and 4000-
fold) can engage and kill autologous tumor.
4.Conclusion
We were able to establish suﬃcientlyexpandingTILbulkcul-
tures in ﬁve weeks from the majority of included melanoma
patients. Further expansion by REP generated a mean ex-
pansion fold of 1400 in two weeks, ensuring the feasibility to
reach clinicalrelevant quantities for clinicaltesting. Based on
earlier studies of T-cell therapy of melanoma patients were
as low as 1,3 × 109 infused cells containing 30% MART-1-
speciﬁc CD8+ T-cells mediated a complete clinical response
[17], we estimate that a minimum of 3 × 109 cells are
required to obtain a therapeutic eﬀect. Cell-based analysis
revealed an oligoclonal composition of T eﬀector memory
cells, predominated by CD8+ cells showing an intermediate
to late stage of diﬀerentiation after REP. TIL retained the
functional capacity measured by INFγ release and lytic
activity against autologous tumor. Notably, we did not ﬁnd
diﬀerences between the two doses of IL-2 used during TIL6 Journal of Skin Cancer
culturing, and even further lowering of IL-2 dose to
3000IU/mL is now the standard used in TIL expansion at
other centres. Finally, there were no signiﬁcant inﬂuence on
TIL expansion kinetics or phenotypes by pretreatment, age
or performance status of the patients.
5.Perspectives
In a recently initiated clinical trial of TIL-based ACT, low-
dose IL-2, and lymphodepletion preconditioning, one out of
ﬁve treated melanoma patients has obtained an ongoing par-
tial response (+13 months). We are currently screening the
TIL cultures for the occurrence of tumor associated antigen
(TAA) speciﬁcities by measuring INFγ in Elispot. This en-
ables us to identify the speciﬁc combination of TAA speci-
ﬁcities in each patient, which potentially can be identiﬁed
during immune monitoring of the patient samples. In addi-
tion, we are establishing and validating a ﬂow cytometry-
based method of identifying TAA-speciﬁc T-cell populations
andobtaininformation onthekineticsofT-cell memory and
eﬀector stages before and after treatment. Information pro-
viding more insight into the prognostic values of adoptively
transferred TIL.
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